Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.
Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedFooter and navigation updates removed references to the Moffitt Cancer Center Clinical Trials website and the H. Lee Moffitt Cancer Center and Research Institute. A new Revision: v3.4.2 tag was added.SummaryDifference0.6%
- Check21 days agoChange DetectedA government funding notice was added and the revision stamp updated to v3.4.1 (replacing the previous v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check28 days agoChange DetectedAdded a Show glossary option and new/updated metadata fields (Last Update Submitted that Met QC Criteria and Last Update Posted) with a footer Revision: v3.4.0. Removed or revised items include No FEAR Act data and Revision: v3.3.4.SummaryDifference0.3%
- Check42 days agoChange DetectedFooter revision label updated to v3.3.4, replacing v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check57 days agoChange DetectedNew entries reflect updated study record dates (e.g., last update posted). There are no changes to core content such as eligibility criteria, outcomes, or enrollment.SummaryDifference0.2%
- Check64 days agoChange DetectedLocations now appear as a dedicated section with Florida listed as a site; the Florida Locations header and HHS Vulnerability Disclosure were removed in revision v3.3.3.SummaryDifference0.2%
Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.